tiprankstipranks
Trending News
More News >
Advertisement

INVN - ETF AI Analysis

Compare

Top Page

INVN

Alger Russell Innovation ETF (INVN)

Rating:72Outperform
Price Target:
INVN, the Alger Russell Innovation ETF, earns a solid overall rating thanks to several strong, innovation-focused holdings like Exelixis and Cirrus Logic, which show robust financial performance, positive earnings calls, and healthy growth prospects. Other contributors such as Bill.com and UiPath add to the appeal with strong momentum and strategic focus on AI, though their high valuations and profitability challenges, along with weaker names like Organon and Etsy facing bearish trends and operational issues, introduce risk. Investors should also note that many top holdings share themes of high growth and rich valuations, which can make the fund more sensitive to market swings in growth and tech-oriented stocks.
Positive Factors
Innovation-Focused Portfolio
The ETF targets innovative companies in areas like technology and health care, which can benefit from long-term growth trends.
Sector Diversification Within Growth Areas
Holdings are spread across several growth-oriented sectors, so the fund is not tied to just one industry’s fortunes.
Some Strong Individual Stock Performers
A few top holdings have shown strong recent performance, which helps offset weaker names in the portfolio.
Negative Factors
Recent Weak Performance
The ETF has delivered negative returns over the past month, three months, and year-to-date, signaling recent struggles.
High Concentration in Technology and Health Care
Nearly all assets are in technology and health care, which increases risk if these sectors fall out of favor.
Above-Average Expense Ratio for an ETF
The fund’s fee is relatively high for an ETF, which can eat into returns over time, especially when performance is weak.

INVN vs. SPDR S&P 500 ETF (SPY)

INVN Summary

The Alger Russell Innovation ETF (INVN) tracks the Alger Russell Innovation Index, focusing on large U.S. companies that are leaders in new technologies and medical advances. It holds innovative names like Lyft and Electronic Arts, along with many other tech and health care firms. Someone might invest in this ETF to seek long-term growth by spreading their money across a basket of forward-looking companies instead of picking individual stocks. A key risk is that it is heavily tilted toward technology and health care, so its price can rise and fall sharply with those sectors and the overall stock market.
How much will it cost me?The Alger Russell Innovation ETF (Ticker: INVN) has an expense ratio of 0.55%, which means you’ll pay $5.50 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, focusing on innovative large-cap companies rather than tracking a broad index. Active management typically involves higher costs due to research and portfolio adjustments.
What would affect this ETF?The Alger Russell Innovation ETF could benefit from continued advancements in technology and healthcare, as these sectors make up a significant portion of its portfolio and are often drivers of innovation. However, rising interest rates or economic slowdowns may negatively impact growth-focused companies, particularly in consumer cyclical and technology sectors. Regulatory changes or geopolitical tensions in the U.S., where the ETF is primarily focused, could also influence its performance.

INVN Top 10 Holdings

INVN is leaning hard into U.S. innovation, with a tech-and-health-care backbone that really sets the tone. Cirrus Logic has been one of the bright spots, quietly climbing and helping to offset weakness elsewhere, while Organon and Exelixis are keeping the health-care side relatively steady. On the other hand, high-profile names like UiPath, Nutanix, Lyft, and Etsy have been lagging, acting like a headwind on recent returns. Overall, the fund is concentrated in innovative U.S. growth stories, but several of its key bets are currently losing steam.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Lyft2.55%$373.05K$5.47B8.45%
69
Neutral
Etsy2.50%$366.34K$5.19B10.03%
57
Neutral
UiPath2.41%$352.68K$5.72B-9.01%
72
Outperform
Electronic Arts2.35%$344.50K$50.32B55.58%
70
Outperform
Corcept Therapeutics2.28%$334.10K$3.83B-39.11%
76
Outperform
Bill.com Holdings2.25%$329.37K$4.37B-14.31%
74
Outperform
Exelixis2.19%$320.45K$10.66B6.43%
78
Outperform
Cirrus Logic2.17%$317.48K$7.30B40.67%
79
Outperform
Nutanix2.14%$314.22K$10.89B-47.97%
62
Neutral
Organon2.13%$311.58K$1.87B-49.90%
53
Neutral

INVN Technical Analysis

Technical Analysis Sentiment
Negative
Last Price
Price Trends
50DMA
20.68
Negative
100DMA
20.88
Negative
200DMA
20.29
Negative
Market Momentum
MACD
-0.37
Negative
RSI
42.55
Neutral
STOCH
80.15
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For INVN, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 19.48, equal to the 50-day MA of 20.68, and equal to the 200-day MA of 20.29, indicating a bearish trend. The MACD of -0.37 indicates Negative momentum. The RSI at 42.55 is Neutral, neither overbought nor oversold. The STOCH value of 80.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INVN.

INVN Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$11.25M0.55%
72
Outperform
$95.68M0.30%
72
Outperform
$92.11M0.32%
73
Outperform
$89.48M0.45%
69
Neutral
$86.13M0.89%
69
Neutral
$76.67M0.70%
72
Outperform
Performance Comparison
Ticker
Company Name
Price
Change
% Change
INVN
Alger Russell Innovation ETF
19.33
0.48
2.55%
LVDS
JPMorgan Fundamental Data Science Large Value ETF
RWLC
Rayliant Quantitative Developed Market Equity ETF
ACEP
ARS Core Equity Portfolio ETF
EGGY
NestYield Dynamic Income Shield ETF
HUSV
First Trust Horizon Managed Volatility Domestic ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement